Mosunetuzumab Expands Promise in Mantle Cell and Marginal Zone Lymphoma: Phase II Results
Mosunetuzumab showed early promise for improving outcomes in two key lymphoma subtypes with 88% response rates in MCL.
Non-Hodgkin Lymphoma
Sonrotoclax (BGB-11417) in Relapsed or Refractory Mantle Cell Lymphoma: FDA Accelerated Approval Based on Phase I/II Data
Sonrotoclax (BGB-11417; Beqalzi) is a next-generation, highly selective B-cell lymphoma 2 (BCL-2) inhibitor that recently received accelerated approval from the U.S. Food and Drug Administration (FDA) on May 13, 2026, for the treatment of adults with...
View More
Latest Conference News
View More
Circulating Tumor DNA Outperforms PET Imaging for Minimal Residual Disease Detection in Large B-Cell Lymphoma
ctDNA detection after LBCL therapy predicts 97% vs 29% progression-free survival, superior to PET scans for determining true remission status.
POLARGO Trial: Polatuzumab Vedotin Improves Survival in Relapsed/Refractory DLBCL
40% reduction in death risk with Pola-R-GemOx vs R-GemOx alone in relapsed/refractory DLBCL (HR 0.60, P=.0017) – POLARGO trial results.